News

Elutia to Present at the H.C. Wainwright 25th Annual Global Investment Conference

SILVER SPRING, Md., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference. The presentation will take place in New York on Wednesday, September 13, 2023, at 2:30 pm ET.

09/08/2023

Aziyo Biologics Announces Publication of a CanGaroo® Case Study Demonstrating Bioenvelope Benefits for Reoperative Procedures

Case provides first histologic evidence that CanGaroo can catalyze development of new healthy tissue layer within an existing cardiac implantable electronic device (CIED) pocket

08/30/2023

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is Aziyo Biologics, Inc. (AZYO) a buy, sell, or hold?

Aziyo Biologics, Inc. (AZYO) can sell. Click on Rating Page for detail.

What is Aziyo Biologics, Inc.'s stock price?

The price of Aziyo Biologics, Inc. (AZYO) is 1.49 and it was updated on 2024-07-27 07:02:25.

Is Aziyo Biologics, Inc. (AZYO) overvalued or undervalued?

Currently Aziyo Biologics, Inc. (AZYO) is in undervalued.

News

From:

To:

News
Aziyo Biologics, Inc. (AZYO) Q2 2023 Earnings Call Transcript Aziyo Biologics, Inc. (NASDAQ:AZYO ) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Matt Steinberg - FINN Partners Randy Mills - President and Chief Executive Officer Matthew Ferguson - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Operator Good day, ladies and gentlemen. Welcome to the Aziyo Biologics' Second Quarter 2023 Financial Results Conference Call. Sun, Aug. 20, 2023
Aziyo Biologics Reports Second Quarter 2023 Financial Results - Transformation Continues to Drug-Eluting Biomatrix Company Negotiating multiple LOIs to divest Orthopedic business CanGaroo® RM 510(k) resubmission to the FDA remains on track SimpliDerm® quarterly net sales up 32% year-over-year Successful transfer of Cardiovascular product distribution to LeMaitre Vascular SILVER SPRING, Md., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today provided a business update and reported financial results for the second quarter ended June 30, 2023. Mon, Aug. 14, 2023
Aziyo Biologics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023 SILVER SPRING, Md., July 31, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that it will release its second quarter 2023 financial results after market close on Monday, August 14, 2023. Members of the Company's management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. Mon, Jul. 31, 2023
Aziyo Biologics Announces Voluntary Recall of Viable Bone Matrix Products SILVER SPRING, Md., July 13, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced a voluntary recall of its viable bone matrix products, which are bone repair products made from human tissue that are used primarily in orthopedic and spinal procedures. Thu, Jul. 13, 2023
Aziyo Biologics, Inc. (AZYO) Q1 2023 Earnings Call Transcript Aziyo Biologics, Inc. (NASDAQ:AZYO ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Matt Steinberg - Investor Relations Randy Mills - Chief Executive Officer Matt Ferguson - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Operator Good day, ladies and gentlemen. Welcome to the Aziyo Biologics First Quarter 2023 Financial Results Conference Call. Sun, May. 14, 2023

Transcripts

Transcipts Data
Aziyo Biologics, Inc. (AZYO) on Q2 2023 Results - Earnings Call Transcript SA Transcripts Sun, Aug. 20, 2023
Aziyo Biologics, Inc. (AZYO) on Q1 2023 Results - Earnings Call Transcript SA Transcripts Sun, May. 14, 2023
Aziyo Biologics, Inc. (AZYO) on Q4 2022 Results - Earnings Call Transcript SA Transcripts Wed, Mar. 22, 2023
Aziyo Biologics, Inc. (AZYO) on Q3 2022 Results - Earnings Call Transcript SA Transcripts Tue, Nov. 15, 2022
Aziyo Biologics, Inc. (AZYO) on Q2 2022 Results - Earnings Call Transcript SA Transcripts Sat, Aug. 13, 2022
Aziyo Biologics, Inc. (AZYO) on Q1 2022 Results - Earnings Call Transcript SA Transcripts Mon, May. 09, 2022
Aziyo Biologics, Inc. (AZYO) on Q4 2021 Results - Earnings Call Transcript SA Transcripts Thu, Mar. 03, 2022
Aziyo Biologics, Inc. (AZYO) on Q3 2021 Results - Earnings Call Transcript SA Transcripts Tue, Nov. 09, 2021
Aziyo Biologics, Inc. (AZYO) on Q2 2021 Results - Earnings Call Transcript SA Transcripts Mon, Aug. 09, 2021
Aziyo Biologics, Inc. (AZYO) on Q1 2021 Results - Earnings Call Transcript SA Transcripts Mon, May. 10, 2021

SEC Filings

SEC Filings
Aziyo Biologics, Inc. (AZYO) - SC 13G/A SEC Filings 02/20/2024
Aziyo Biologics, Inc. (AZYO) - 4/A SEC Filings 02/20/2024
Aziyo Biologics, Inc. (AZYO) - 3/A SEC Filings 02/20/2024
Aziyo Biologics, Inc. (AZYO) - SC 13G SEC Filings 02/14/2024
Aziyo Biologics, Inc. (AZYO) - 424B3 SEC Filings 02/14/2024
Aziyo Biologics, Inc. (AZYO) - SC 13G/A SEC Filings 02/07/2024
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 02/02/2024
Aziyo Biologics, Inc. (AZYO) - 4 SEC Filings 02/02/2024
Aziyo Biologics, Inc. (AZYO) - S-8 SEC Filings 01/25/2024
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 01/12/2024
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 01/10/2024
Aziyo Biologics, Inc. (AZYO) - SC 13D/A SEC Filings 01/09/2024
Aziyo Biologics, Inc. (AZYO) - 4 SEC Filings 01/08/2024
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 12/27/2023
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 12/08/2023
Aziyo Biologics, Inc. (AZYO) - EFFECT SEC Filings 12/05/2023
Aziyo Biologics, Inc. (AZYO) - 424B3 SEC Filings 12/05/2023
Aziyo Biologics, Inc. (AZYO) - SC 13G SEC Filings 12/04/2023
Aziyo Biologics, Inc. (AZYO) - S-3 SEC Filings 11/20/2023
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 11/20/2023
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 11/15/2023
Aziyo Biologics, Inc. (AZYO) - 10-Q - Quarterly Report SEC Filings 11/14/2023
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 11/13/2023
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 11/09/2023
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 11/07/2023
Aziyo Biologics, Inc. (AZYO) - SC 13D/A SEC Filings 10/06/2023
Aziyo Biologics, Inc. (AZYO) - 4 SEC Filings 10/05/2023
Aziyo Biologics, Inc. (AZYO) - 3 SEC Filings 10/05/2023
Aziyo Biologics, Inc. (AZYO) - D SEC Filings 10/03/2023
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 09/21/2023
Aziyo Biologics, Inc. (AZYO) - 4 SEC Filings 09/21/2023
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 09/19/2023
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 09/07/2023
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 08/14/2023
Aziyo Biologics, Inc. (AZYO) - 10-Q - Quarterly Report SEC Filings 08/14/2023
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 07/13/2023
Aziyo Biologics, Inc. (AZYO) - 4 SEC Filings 06/23/2023
Aziyo Biologics, Inc. (AZYO) - 4 SEC Filings 06/12/2023
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 06/09/2023
Aziyo Biologics, Inc. (AZYO) - 10-Q - Quarterly Report SEC Filings 05/12/2023
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 05/10/2023
Aziyo Biologics, Inc. (AZYO) - 4 SEC Filings 04/28/2023
Aziyo Biologics, Inc. (AZYO) - DEFA14A SEC Filings 04/27/2023
Aziyo Biologics, Inc. (AZYO) - DEF 14A SEC Filings 04/27/2023
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 04/21/2023
Aziyo Biologics, Inc. (AZYO) - SC 13G/A SEC Filings 04/07/2023
Aziyo Biologics, Inc. (AZYO) - 4 SEC Filings 03/27/2023
Aziyo Biologics, Inc. (AZYO) - 10-K - Current report SEC Filings 03/23/2023
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 03/22/2023
Aziyo Biologics, Inc. (AZYO) - SC 13G/A SEC Filings 03/21/2023
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 03/20/2023
Aziyo Biologics, Inc. (AZYO) - 4 SEC Filings 03/09/2023
Aziyo Biologics, Inc. (AZYO) - SC 13G/A SEC Filings 02/14/2023
Aziyo Biologics, Inc. (AZYO) - SC 13G/A SEC Filings 02/13/2023
Aziyo Biologics, Inc. (AZYO) - 4 SEC Filings 02/13/2023
Aziyo Biologics, Inc. (AZYO) - 3 SEC Filings 02/13/2023
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 01/09/2023
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 12/30/2022
Aziyo Biologics, Inc. (AZYO) - 4 SEC Filings 12/28/2022
Aziyo Biologics, Inc. (AZYO) - 4 SEC Filings 12/27/2022
Aziyo Biologics, Inc. (AZYO) - 4 SEC Filings 12/16/2022
Aziyo Biologics, Inc. (AZYO) - SC 13G/A SEC Filings 12/15/2022
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 12/15/2022
Aziyo Biologics, Inc. (AZYO) - 3 SEC Filings 12/15/2022
Aziyo Biologics, Inc. (AZYO) - 4 SEC Filings 12/12/2022
Aziyo Biologics, Inc. (AZYO) - SC 13D/A SEC Filings 12/07/2022
Aziyo Biologics, Inc. (AZYO) - 4 SEC Filings 12/07/2022
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 12/05/2022
Aziyo Biologics, Inc. (AZYO) - 4 SEC Filings 12/05/2022
Aziyo Biologics, Inc. (AZYO) - 424B5 SEC Filings 12/02/2022
Aziyo Biologics, Inc. (AZYO) - 424B5 SEC Filings 11/30/2022
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 11/28/2022
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 11/17/2022
Aziyo Biologics, Inc. (AZYO) - 10-Q - Quarterly Report SEC Filings 11/14/2022
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 10/24/2022
Aziyo Biologics, Inc. (AZYO) - 4 SEC Filings 10/24/2022
Aziyo Biologics, Inc. (AZYO) - 3 SEC Filings 10/21/2022
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 10/13/2022
Aziyo Biologics, Inc. (AZYO) - 4 SEC Filings 09/12/2022
Aziyo Biologics, Inc. (AZYO) - EFFECT SEC Filings 09/09/2022
Aziyo Biologics, Inc. (AZYO) - CORRESP SEC Filings 09/07/2022
Aziyo Biologics, Inc. (AZYO) - UPLOAD SEC Filings 09/06/2022
Aziyo Biologics, Inc. (AZYO) - S-3 SEC Filings 08/31/2022
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 08/31/2022
Aziyo Biologics, Inc. (AZYO) - 3 SEC Filings 08/29/2022
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 08/15/2022
Aziyo Biologics, Inc. (AZYO) - 10-Q - Quarterly Report SEC Filings 08/15/2022
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 08/11/2022
Aziyo Biologics, Inc. (AZYO) - 4 SEC Filings 06/23/2022
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 06/21/2022
Aziyo Biologics, Inc. (AZYO) - 4 SEC Filings 06/09/2022
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 06/08/2022
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 06/03/2022
Aziyo Biologics, Inc. (AZYO) - 10-Q - Quarterly Report SEC Filings 05/10/2022
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 05/09/2022
Aziyo Biologics, Inc. (AZYO) - DEFA14A SEC Filings 04/22/2022
Aziyo Biologics, Inc. (AZYO) - DEF 14A SEC Filings 04/22/2022
Aziyo Biologics, Inc. (AZYO) - 4 SEC Filings 03/10/2022
Aziyo Biologics, Inc. (AZYO) - 10-K - Current report SEC Filings 03/08/2022
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 03/03/2022
Aziyo Biologics, Inc. (AZYO) - SC 13G/A SEC Filings 02/14/2022
Aziyo Biologics, Inc. (AZYO) - EFFECT SEC Filings 02/04/2022
Aziyo Biologics, Inc. (AZYO) - 424B3 SEC Filings 02/04/2022
Aziyo Biologics, Inc. (AZYO) - EFFECT SEC Filings 02/03/2022
Aziyo Biologics, Inc. (AZYO) - CORRESP SEC Filings 02/02/2022
Aziyo Biologics, Inc. (AZYO) - UPLOAD SEC Filings 01/28/2022
Aziyo Biologics, Inc. (AZYO) - S-3 SEC Filings 01/21/2022
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 01/21/2022
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 01/07/2022
Aziyo Biologics, Inc. (AZYO) - D SEC Filings 12/22/2021
Aziyo Biologics, Inc. (AZYO) - SC 13D SEC Filings 12/20/2021
Aziyo Biologics, Inc. (AZYO) - SC 13G SEC Filings 12/17/2021
Aziyo Biologics, Inc. (AZYO) - SC 13G SEC Filings 12/16/2021
Aziyo Biologics, Inc. (AZYO) - 4 SEC Filings 12/15/2021
Aziyo Biologics, Inc. (AZYO) - 4 SEC Filings 12/10/2021
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 12/08/2021
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 11/22/2021
Aziyo Biologics, Inc. (AZYO) - 10-Q - Quarterly Report SEC Filings 11/10/2021
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 11/09/2021
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 10/25/2021
Aziyo Biologics, Inc. (AZYO) - 4 SEC Filings 09/01/2021
Aziyo Biologics, Inc. (AZYO) - 3 SEC Filings 09/01/2021
Aziyo Biologics, Inc. (AZYO) - 8-K/A - Current report SEC Filings 08/10/2021
Aziyo Biologics, Inc. (AZYO) - 10-Q - Quarterly Report SEC Filings 08/10/2021
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 08/09/2021
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 07/06/2021
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 06/22/2021
Aziyo Biologics, Inc. (AZYO) - SC 13G SEC Filings 06/09/2021
Aziyo Biologics, Inc. (AZYO) - 4 SEC Filings 06/09/2021
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 06/08/2021
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 06/07/2021
Aziyo Biologics, Inc. (AZYO) - 4 SEC Filings 05/12/2021
Aziyo Biologics, Inc. (AZYO) - 4 SEC Filings 05/11/2021
Aziyo Biologics, Inc. (AZYO) - 10-Q - Quarterly Report SEC Filings 05/07/2021
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 05/04/2021
Aziyo Biologics, Inc. (AZYO) - DEFA14A SEC Filings 04/23/2021
Aziyo Biologics, Inc. (AZYO) - DEF 14A SEC Filings 04/23/2021
Aziyo Biologics, Inc. (AZYO) - 10-K - Current report SEC Filings 03/15/2021
Aziyo Biologics, Inc. (AZYO) - 4 SEC Filings 03/10/2021
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 03/02/2021
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 03/01/2021
Aziyo Biologics, Inc. (AZYO) - SC 13G SEC Filings 02/16/2021
Aziyo Biologics, Inc. (AZYO) - 4 SEC Filings 12/10/2020
Aziyo Biologics, Inc. (AZYO) - 10-Q - Quarterly Report SEC Filings 11/20/2020
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 11/19/2020
Aziyo Biologics, Inc. (AZYO) - 8-K - Current report SEC Filings 10/13/2020
Aziyo Biologics, Inc. (AZYO) - 4 SEC Filings 10/13/2020
Aziyo Biologics, Inc. (AZYO) - EFFECT SEC Filings 10/08/2020
Aziyo Biologics, Inc. (AZYO) - S-8 SEC Filings 10/08/2020
Aziyo Biologics, Inc. (AZYO) - 424B4 SEC Filings 10/08/2020
Aziyo Biologics, Inc. (AZYO) - 4 SEC Filings 10/08/2020
Aziyo Biologics, Inc. (AZYO) - EFFECT SEC Filings 10/07/2020
Aziyo Biologics, Inc. (AZYO) - 3 SEC Filings 10/07/2020
Aziyo Biologics, Inc. (AZYO) - CERT SEC Filings 10/05/2020
Aziyo Biologics, Inc. (AZYO) - CORRESP SEC Filings 10/02/2020
Aziyo Biologics, Inc. (AZYO) - S-1/A SEC Filings 09/30/2020
Aziyo Biologics, Inc. (AZYO) - 8-A12B SEC Filings 09/30/2020
Aziyo Biologics, Inc. (AZYO) - S-1 SEC Filings 09/14/2020
Aziyo Biologics, Inc. (AZYO) - D SEC Filings 09/14/2020
Aziyo Biologics, Inc. (AZYO) - CORRESP SEC Filings 09/14/2020
Aziyo Biologics, Inc. (AZYO) - UPLOAD SEC Filings 09/02/2020
Aziyo Biologics, Inc. (AZYO) - DRS/A SEC Filings 08/17/2020
Aziyo Biologics, Inc. (AZYO) - DRSLTR SEC Filings 08/14/2020
Aziyo Biologics, Inc. (AZYO) - UPLOAD SEC Filings 08/07/2020
Aziyo Biologics, Inc. (AZYO) - DRS SEC Filings 07/10/2020
Aziyo Biologics, Inc. (AZYO) - D SEC Filings 12/18/2019
Aziyo Biologics, Inc. (AZYO) - D SEC Filings 08/06/2018
Aziyo Biologics, Inc. (AZYO) - D SEC Filings 06/09/2017

Press Releases

StockPrice Release
Elutia to present at the h.c. wainwright 25th annual global investment conference 09/08/2023
Aziyo biologics announces publication of a cangaroo® case study demonstrating bioenvelope benefits for reoperative procedures 08/30/2023
Aziyo biologics reports second quarter 2023 financial results - transformation continues to drug-eluting biomatrix company 08/14/2023
Aziyo biologics to report second quarter 2023 financial results on monday, august 14, 2023 07/31/2023
Aziyo biologics announces voluntary recall of viable bone matrix products 07/13/2023
Aziyo biologics presents positive clinical data on cangaroo® biologic envelope 05/19/2023
Aziyo biologics to report first quarter 2023 financial results on wednesday, may 10, 2023 05/03/2023
Aziyo biologics and lemaitre vascular partner for the distribution of aziyo's cardiovascular portfolio 04/20/2023
Aziyo biologics reports record full year 2022 revenues 03/22/2023
Aziyo biologics and sientra announce simpliderm® partnership to improve women's access to biologics for soft tissue reconstruction 03/22/2023
Aziyo biologics to report fourth quarter and full year 2022 financial results on wednesday, march 22, 2023 03/15/2023
Aziyo biologics to present at the cowen 43rd annual health care conference 02/27/2023
Aziyo biologics announces record annual net sales in preliminary (unaudited) fourth quarter and full year 2022 topline results 01/09/2023
Aziyo biologics announces funding of additional $4 million term loan with swk holdings corporation 12/15/2022
Aziyo biologics, inc. announces pricing of $11.2 million public offering of common stock 12/01/2022
Aziyo biologics, inc. announces proposed public offering of common stock 11/30/2022
Aziyo biologics to participate in upcoming investor conferences 11/21/2022
Swk holdings corporation announces financial results for third quarter 2022 11/09/2022
Aziyo biologics strengthens leadership team and organizes for growth in key markets 10/11/2022
Aziyo biologics appoints michelle leroux williams, ph.d as chief scientific officer 08/26/2022
Aziyo biologics to present at the inaugural gilmartin group emerging growth company showcase 08/17/2022
Aziyo biologics announces $25 million loan facility with swk holdings 08/10/2022
Aziyo biologics co-founder and regenerative medicine pioneer, dr. randy mills, appointed chief executive officer 08/09/2022
Aziyo biologics to report second quarter 2022 financial results on august 11, 2022 07/28/2022
Aziyo biologics appoints dr. c. randal mills as interim president and ceo 06/21/2022
Aziyo biologics provides business update and reports first quarter 2022 financial results 05/09/2022
Aziyo biologics to report first quarter 2022 financial results on monday, may 9, 2022 04/25/2022
Aziyo biologics announces upcoming kol call hosted by cowen 04/12/2022
Aziyo biologics to participate in the lytham partners spring 2022 investor conference 03/31/2022
Aziyo biologics to report fourth quarter and full year 2021 financial results on thursday, march 3, 2022 02/17/2022
Aziyo biologics to present at the h.c. wainwright bioconnect virtual conference 12/27/2021
Aziyo biologics announces closing of $14.0 million private placement 12/08/2021
Aziyo biologics provides business update and preliminary third quarter 2021 revenue results and announces timing for third quarter 2021 financial results 10/25/2021
Aziyo biologics to participate in the 2021 cantor global healthcare conference 09/15/2021
Aziyo biologics appoints peter g. edwards as general counsel 08/31/2021
Aziyo biologics reports first quarter 2021 financial results and increases 2021 revenue guidance 05/04/2021
Aziyo biologics to participate in the truist securities life sciences summit 04/26/2021
Aziyo biologics to report first quarter 2021 financial results on tuesday, may 4, 2021 04/20/2021
Aziyo biologics reports fourth quarter and full year 2020 financial results 03/01/2021
Aziyo biologics to participate in the cowen 41st annual health care conference 02/18/2021
Aziyo biologics announces first patient enrolled in heal study 02/17/2021
Aziyo biologics to report fourth quarter and full year 2020 financial results on monday, march 1, 2021 02/15/2021
Aziyo biologics announces product design completion for its next generation cangaroo® envelope for implantable electronic devices 02/11/2021
Aziyo biologics announces updated cangaroo® envelope label in european markets to allow for hydration in an antibiotic solution 01/28/2021

More Headlines

News
Aziyo Biologics to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023 SILVER SPRING, Md., May 03, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that it will release its first quarter 2023 financial results after market close on Wednesday, May 10, 2023. Members of the Company's management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. 05/03/2023
Aziyo Biologics, Inc. (AZYO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now Aziyo Biologics, Inc. (AZYO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term. 04/05/2023
Aziyo Biologics, Inc. (AZYO) Q4 2022 Earnings Call Transcript Aziyo Biologics, Inc. (NASDAQ:AZYO ) Q4 2022 Earnings Conference Call March 22, 2023 4:30 PM ET Company Participants Matt Steinberg - Investor Relations, FINN Partners Randy Mills - Chief Executive Officer Matt Ferguson - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Josh Jennings - TD Cowen & Company Operator Good day, ladies and gentlemen, and welcome to the Aziyo Biologics Fourth Quarter and Full Year 2022 Financial Results Call. At this time, all participants are in a listen-only mode. 03/22/2023
ACER's Stock Down on Failure of Phase II Study, Cash Updates ACER announces the failure of its phase IIa study of ACER-801 to treat vasomotor symptoms associated with menopause, along with its extinguishing cash runway. Stock down. 03/20/2023
Aziyo Biologics to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 22, 2023 SILVER SPRING, Md., March 15, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that it will release its fourth quarter and full year 2022 financial results after market close on Wednesday, March 22, 2023. Members of the Company's management team will host a conference call and webcast with accompanying slides starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. 03/15/2023
Aziyo Biologics to Present at the Cowen 43rd Annual Health Care Conference SILVER SPRING, Md., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will present at the Cowen 43rd Annual Health Care Conference. The presentation will take place at the Boston Marriott Copley Place on Monday, March 6, 2023, at 9:50 am ET. 02/27/2023
Aziyo Biologics, Inc. (AZYO) Upgraded to Buy: Here's What You Should Know Aziyo Biologics, Inc. (AZYO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). 01/26/2023
Aziyo Biologics to Participate in Upcoming Investor Conferences SILVER SPRING, Md., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical devices and the patients they treat, today announced that management will be participating in the following investor conferences: 11/21/2022
Aziyo Biologics, Inc. (AZYO) Q3 2022 Earnings Call Transcript Aziyo Biologics, Inc. (NASDAQ:AZYO ) Q3 2022 Results Conference Call November 14, 2022 4:30 PM ET Company Participants Matt Steinberg - Fin Partners Randy Mills - CEO Matt Ferguson - CFO Conference Call Participants Josh Jennings - Cowen Simran Kaur - Piper Sandler David Rescott - Truist Securities Operator Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Aziyo Biologics Third Quarter 2022 Earnings Conference Call. 11/15/2022
Aziyo Biologics, Inc. (AZYO) Reports Q3 Loss, Tops Revenue Estimates Aziyo Biologics, Inc. (AZYO) delivered earnings and revenue surprises of -10.61% and 1.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? 11/14/2022
Aziyo Biologics to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase SILVER SPRING, Md., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company, today announced the company will present at the upcoming Inaugural Gilmartin Group Emerging Growth Company Showcase, taking place virtually. Members of management are scheduled to present on Wednesday, August 31, 2022 at 10:30 am ET / 7:30 am PT. 08/17/2022
Aziyo Biologics (AZYO) CEO Randy Mills on Q2 2022 Results - Earnings Call Transcript Aziyo Biologics, Inc. (NASDAQ:AZYO ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Leigh Salvo - IR Kevin Rakin - Executive Chairman Randy Mills - CEO Matthew Ferguson - CFO Conference Call Participants Josh Jennings - Cowen David Rescott - Truist Ross Osborn - Cantor Fitzgerald Operator Good day. And thank you for standing by. 08/13/2022
Aziyo Biologics to Report Second Quarter 2022 Financial Results on August 11, 2022 SILVER SPRING, Md., July 28, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it will release second quarter 2022 financial results after market close on Thursday, August 11, 2022. Members of the Company's management team will host a conference call and webcast with accompanying slides starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. 07/28/2022
Is Aziyo Biologics (AZYO) Outperforming Other Medical Stocks This Year? Here is how Aziyo Biologics, Inc. (AZYO) and AMN Healthcare Services (AMN) have performed compared to their sector so far this year. 07/20/2022
Aziyo Biologics, Inc. (AZYO) Moves 7.8% Higher: Will This Strength Last? Aziyo Biologics, Inc. (AZYO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. 06/27/2022
Aziyo Biologics, Inc. (AZYO) CEO Ronald Lloyd on Q1 2022 Results - Earnings Call Transcript Aziyo Biologics, Inc. (NASDAQ:AZYO ) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Ronald Lloyd – President and Chief Executive Officer Matthew Ferguson – Chief Financial Officer Leigh Salvo – Investor Relations, Gilmartin Group, LLC Conference Call Participants David Rescott – Truist Securities Operator Thank you for standing by and welcome to Aziyo Biologics Q1 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. 05/09/2022
Aziyo Biologics, Inc. (AZYO) Reports Q1 Loss, Tops Revenue Estimates Aziyo Biologics, Inc. (AZYO) delivered earnings and revenue surprises of 3.23% and 6.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock? 05/09/2022
Aziyo Biologics to Report First Quarter 2022 Financial Results on Monday, May 9, 2022 SILVER SPRING, Md., April 25, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it plans to release its first quarter 2022 earnings results after market close on Monday, May 9, 2022. Management will host a conference call to review the Company's financial performance starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call will be concurrently webcast. 04/25/2022
Aziyo Biologics to Participate in the Lytham Partners Spring 2022 Investor Conference SILVER SPRING, Md., March 31, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it will be participating in the Lytham Partners Spring 2022 Investor Conference taking place virtually on April 4-7, 2022. 03/31/2022
Aziyo Biologics, Inc. (AZYO) Reports Q4 Loss, Lags Revenue Estimates Aziyo Biologics, Inc. (AZYO) delivered earnings and revenue surprises of -28.13% and 2.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? 03/03/2022
Aziyo Biologics, Inc. (AZYO) CEO Ronald Lloyd on Q4 2021 Results - Earnings Call Transcript Aziyo Biologics, Inc. (AZYO) CEO Ronald Lloyd on Q4 2021 Results - Earnings Call Transcript 03/03/2022
Aziyo Biologics to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 3, 2022 SILVER SPRING, Md., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it plans to release its fourth quarter and full year 2021 earnings results after market close on Thursday, March 3, 2022. Management will host a conference call to review the Company's financial performance starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call will be concurrently webcast. 02/17/2022
All You Need to Know About Aziyo Biologics, Inc. (AZYO) Rating Upgrade to Buy Aziyo Biologics, Inc. (AZYO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. 02/14/2022
Aziyo Biologics to Present at the H.C. Wainwright Bioconnect Virtual Conference SILVER SPRING, Md., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that members of management will present at the upcoming H.C. Wainwright Bioconnect Virtual Conference. 12/27/2021
Aziyo Biologics, Inc. (AZYO) CEO Ronald Lloyd on Q3 2021 Results - Earnings Call Transcript Aziyo Biologics, Inc. (AZYO) CEO Ronald Lloyd on Q3 2021 Results - Earnings Call Transcript 11/09/2021
Aziyo Biologics, Inc. (AZYO) Reports Q3 Loss, Misses Revenue Estimates Aziyo Biologics, Inc. (AZYO) delivered earnings and revenue surprises of -32.79% and -0.47%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock? 11/09/2021
Aziyo Biologics Provides Business Update and Preliminary Third Quarter 2021 Revenue Results and Announces Timing for Third Quarter 2021 Financial Results SILVER SPRING, Md., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it was informed by Medtronic that, after conducting a thorough review of customer and patient needs, Medtronic has made the decision to cease distribution of Cellular Bone Matrix (CBM) products. As a result of this decision, the two companies are working toward a mutual termination of their FiberCel distribution agreement. 10/25/2021
Aziyo Biologics to Participate in the 2021 Cantor Global Healthcare Conference SILVER SPRING, Md., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the Company will participate in the upcoming 2021 Cantor Global Healthcare Conference. 09/15/2021
Aziyo Biologics Appoints Peter G. Edwards as General Counsel SILVER SPRING, Md., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the appointment of Peter G. Edwards as General Counsel. 08/31/2021
Aziyo Biologics, Inc. (AZYO) CEO Ronald Lloyd on Q2 2021 Results - Earnings Call Transcript Aziyo Biologics, Inc. (AZYO) CEO Ronald Lloyd on Q2 2021 Results - Earnings Call Transcript 08/09/2021
Aziyo Biologics, Inc. (AZYO) CEO Ronald Lloyd on Q1 2021 Results - Earnings Call Transcript Aziyo Biologics, Inc. (AZYO) CEO Ronald Lloyd on Q1 2021 Results - Earnings Call Transcript 05/10/2021
Aziyo Biologics Reports First Quarter 2021 Financial Results and Increases 2021 Revenue Guidance SILVER SPRING, Md., May 04, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today reported financial results for the three months ended March 31, 2021. 05/04/2021
Aziyo Biologics to Participate in the Truist Securities Life Sciences Summit SILVER SPRING, Md., April 26, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the Company will participate in the upcoming Truist Securities Life Sciences Summit. 04/26/2021
Aziyo Biologics, Inc. (AZYO) CEO Ronald Lloyd on Q4 2020 Results - Earnings Call Transcript Aziyo Biologics, Inc. (AZYO) CEO Ronald Lloyd on Q4 2020 Results - Earnings Call Transcript 03/01/2021
Aziyo Biologics Reports Fourth Quarter and Full Year 2020 Financial Results SILVER SPRING, Md., March 01, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today reported financial results for the fourth quarter and full year ended December 31, 2020. 03/01/2021
Aziyo Biologics to Participate in the Cowen 41st Annual Health Care Conference SILVER SPRING, Md., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the Company will participate in the upcoming Cowen 41st Annual Health Care Conference. 02/18/2021
Aziyo Biologics Announces First Patient Enrolled in HEAL Study SILVER SPRING, Md., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced today the first patient enrolled in the HEAL Study, investigating the biologic and clinical effects of device envelopes which are placed around cardiovascular implantable electronic devices (“CIEDs”) at the time of implantation surgery. 02/17/2021
Aziyo Biologics to Report Fourth Quarter and Full Year 2020 Financial Results on Monday, March 1, 2021 SILVER SPRING, Md., Feb. 15, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it plans to release its fourth quarter and full year earnings results after market close on Monday, March 1, 2021. Management will host a conference call to review the Company's financial performance starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call will be concurrently webcast. 02/15/2021
Aziyo Biologics Announces Product Design Completion for its Next Generation CanGaroo® Envelope for Implantable Electronic Devices SILVER SPRING, Md., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced today product design completion for CanGaroo® with antibiotics, the next generation of the Company's CanGaroo Envelope. 02/11/2021
Aziyo Biologics Announces Updated CanGaroo® Envelope Label in European Markets to Allow for Hydration in an Antibiotic Solution SILVER SPRING, Md., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced that it has received CE Mark approval for updated labeling of the Company's biological CanGaroo® Envelope to allow for the addition of the antibiotic gentamicin. While the indications of the CanGaroo Envelope remain unchanged, this approval now permits the envelope to be hydrated in a gentamicin solution during device preparation prior to implantation at the discretion of the prescribing physician. Pre-clinical testing has demonstrated hydrating the CanGaroo Envelope in gentamicin prior to use can reduce or inhibit bacterial growth. 01/28/2021

Unlock

AZYO Ratings Summary

AZYO Quant Ranking